{"transactions":[{"id":690840,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:23:28.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":131396,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":131396,"derivative":{"exercise_price":4.14,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":131396},"source":{"system":"sec-edgar","filing":"0001748961-26-000002","document":"form4-08112026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000174896126000002/form4-08112026_080820.xml","form_type":"4"}},{"id":690839,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:23:28.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":131396,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":131396},"source":{"system":"sec-edgar","filing":"0001748961-26-000002","document":"form4-08112026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000174896126000002/form4-08112026_080820.xml","form_type":"4"}},{"id":690838,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:23:28.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":18588,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option vested on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":18588,"derivative":{"exercise_price":4.14,"expiration_date":"2034-02-05","underlying":"Class A Common Stock","underlying_shares":18588},"source":{"system":"sec-edgar","filing":"0001748961-26-000002","document":"form4-08112026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000174896126000002/form4-08112026_080820.xml","form_type":"4"}},{"id":690837,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:23:28.000Z","date":"2026-08-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18588,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on August 7, 2026 (the \"Effective Date\"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a \"Retention Period\" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The \"Retention Period\" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option vested on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":13.99,"expiration_date":"2034-02-05","underlying":"Class A Common Stock","underlying_shares":18588},"source":{"system":"sec-edgar","filing":"0001748961-26-000002","document":"form4-08112026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000174896126000002/form4-08112026_080820.xml","form_type":"4"}},{"id":690836,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-11T20:23:28.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":50000,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001748961-26-000002","document":"form4-08112026_080820.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000174896126000002/form4-08112026_080820.xml","form_type":"4"}},{"id":816550,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-04-03T19:25:25.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":110000,"derivative":{"exercise_price":4.07,"expiration_date":"2036-03-31","underlying":"Class A Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001748961-26-000001","document":"form4-04032026_070420.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000174896126000001/form4-04032026_070420.xml","form_type":"4"}},{"id":1291877,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-01-30T01:33:11.000Z","date":"2025-01-27","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest on February 27, 2025 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":45000,"derivative":{"exercise_price":5.19,"expiration_date":"2035-01-26","underlying":"Class A Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001415889-25-002309","document":"form4-01302025_010108.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000141588925002309/form4-01302025_010108.xml","form_type":"4"}},{"id":1389367,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-08T23:20:22.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":131396,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":131396,"derivative":{"exercise_price":18.2,"expiration_date":"2034-10-03","underlying":"Class A Common Stock","underlying_shares":131396},"source":{"system":"sec-edgar","filing":"0001415889-24-024911","document":"form4-10082024_111019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000141588924024911/form4-10082024_111019.xml","form_type":"4"}},{"id":1389366,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-10-08T23:20:22.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":18588,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Agreement and Plan of Merger, dated as of May 10, 2024 (the \"Merger Agreement\"), by and among Reneo Pharmaceuticals, Inc. (\"Reneo\"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo (\"Merger Sub I\"), and OnKure, Inc. (\"OnKure\"), provided for the merger of Merger Sub I with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the \"Merger\"). After completion of the Merger, the combined company was renamed \"OnKure Therapeutics, Inc.\" and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol \"OKUR.\"  Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, (footnote continued in footnote (3))"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(continued from footnote (2)) a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share).  The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on February 5, 2025 and 1/48th of the shares subject to the option vest on the first day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":18588,"derivative":{"exercise_price":13.99,"expiration_date":"2034-02-05","underlying":"Class A Common Stock","underlying_shares":18588},"source":{"system":"sec-edgar","filing":"0001415889-24-024911","document":"form4-10082024_111019.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000141588924024911/form4-10082024_111019.xml","form_type":"4"}},{"id":1801967,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-08-18T20:03:38.000Z","date":"2023-08-16","kind":"exercise","planned":false,"acquired":false,"shares":311297,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested as to 25% of the underlying shares of common stock on September 16, 2020, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter until fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.72,"expiration_date":"2029-09-16","underlying":"Common Stock","underlying_shares":311297},"source":{"system":"sec-edgar","filing":"0001562180-23-006433","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000156218023006433/primarydocument.xml","form_type":"4"}},{"id":1801966,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-18T20:03:38.000Z","date":"2023-08-16","kind":"sale","planned":false,"acquired":false,"shares":311297,"price":8.25,"value":2568200.25,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-23-006433","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000156218023006433/primarydocument.xml","form_type":"4"}},{"id":1801965,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-18T20:03:38.000Z","date":"2023-08-16","kind":"exercise","planned":false,"acquired":true,"shares":311297,"price":3.72,"value":1158024.84,"ownership":{"direct":true},"balance_after":311297,"source":{"system":"sec-edgar","filing":"0001562180-23-006433","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000156218023006433/primarydocument.xml","form_type":"4"}},{"id":2042228,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-30T22:04:32.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the underlying shares of common stock on January 26, 2024, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter."}],"balance_after":60000,"derivative":{"exercise_price":8.38,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001562180-23-000728","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000156218023000728/primarydocument.xml","form_type":"4"}},{"id":2230369,"issuer":{"id":109802,"kind":"organization","name":"INFINITY PHARMACEUTICALS, INC.","symbol":"INFI"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":true}}],"security":"Stock Option(right to buy)","published_at":"2022-06-16T20:42:58.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer."}],"balance_after":45000,"derivative":{"exercise_price":0.679,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001140361-22-023318","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1113148/000114036122023318/form4.xml","form_type":"4"}},{"id":2422593,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-28T21:27:31.000Z","date":"2022-01-26","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested as to 25% of the underlying shares of common stock on January 26, 2023, the first anniversary of the of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested."}],"balance_after":125000,"derivative":{"exercise_price":14.87,"expiration_date":"2032-01-25","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001562180-22-000751","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000156218022000751/primarydocument.xml","form_type":"4"}},{"id":2672445,"issuer":{"id":109802,"kind":"organization","name":"INFINITY PHARMACEUTICALS, INC.","symbol":"INFI"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-06-11T16:16:39.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer."}],"balance_after":30000,"derivative":{"exercise_price":3.43,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-21-020649","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1113148/000114036121020649/form4.xml","form_type":"4"}},{"id":2888809,"issuer":{"id":5820,"kind":"organization","name":"Foghorn Therapeutics Inc.","symbol":"FHTX"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-02T02:26:27.000Z","date":"2021-01-28","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest as to 25% of the underlying shares of common stock on January 28, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option is fully vested."}],"balance_after":100000,"derivative":{"exercise_price":16.63,"expiration_date":"2031-01-27","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-21-003968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1748961/000089924321003968/doc4.xml","form_type":"4"}},{"id":3105768,"issuer":{"id":109802,"kind":"organization","name":"INFINITY PHARMACEUTICALS, INC.","symbol":"INFI"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to\nbuy)","published_at":"2020-06-18T08:30:39.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer."}],"balance_after":30000,"derivative":{"exercise_price":0.92,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-20-017000","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1113148/000089924320017000/doc4.xml","form_type":"4"}},{"id":3393045,"issuer":{"id":109802,"kind":"organization","name":"INFINITY PHARMACEUTICALS, INC.","symbol":"INFI"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-10-16T19:18:42.000Z","date":"2020-10-16","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/8th of the shares on December 31, 2019 and as to 1/8th of the shares at the end of each calendar quarter thereafter, provided that the holder continues to serve as a director of the Issuer."}],"balance_after":60000,"derivative":{"exercise_price":1.14,"expiration_date":"2030-10-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899243-19-025628","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1113148/000089924319025628/doc4.xml","form_type":"4"}},{"id":3702184,"issuer":{"id":109802,"kind":"organization","name":"INFINITY PHARMACEUTICALS, INC.","symbol":"INFI"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-07T16:05:37.000Z","date":"2019-01-04","kind":"grant","acquired":true,"shares":62596,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/48th of the shares on January 31, 2019 and vests as to 1/48th of the shares at the end of each calendar month thereafter."}],"balance_after":62596,"derivative":{"exercise_price":1.24,"expiration_date":"2029-01-04","underlying":"Common Stock","underlying_shares":62596},"source":{"system":"sec-edgar","filing":"0000899243-19-000654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1113148/000089924319000654/doc4.xml","form_type":"4"}},{"id":3850945,"issuer":{"id":109802,"kind":"organization","name":"INFINITY PHARMACEUTICALS, INC.","symbol":"INFI"},"owners":[{"id":24628,"kind":"person","name":"Agresta Samuel","position":1,"cik":"0001748961","reported_name":"Agresta Samuel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-08-07T17:10:07.000Z","date":"2018-08-06","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 12/48th of the shares on August 6, 2019 and vests as to 1/48th of the shares at the end of each calendar month thereafter."}],"balance_after":300000,"derivative":{"exercise_price":1.8,"expiration_date":"2028-08-06","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0000899243-18-021568","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1113148/000089924318021568/doc4.xml","form_type":"4"}}]}